

Giuseppe Fornarini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9457588/giuseppe-fornarini-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

87
papers

1,473
citations

21
h-index

35
g-index

105
ext. papers

1,824
ext. citations

4.5
avg, IF

3.77
L-index

#	Paper	IF	Citations
87	Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223.. <i>Annals of Nuclear Medicine</i> , 2022 , 36, 373	2.5	1
86	Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel.. <i>BMC Medicine</i> , 2022 , 20, 48	11.4	0
85	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359221079580	5.4	0
84	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022 , 12, 727	3.6	0
83	Cardiovascular risk profile and events before and after treatment with anti-VEGF drugs in the setting of a structured cardio-oncologic program. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, e38-e40	3.9	2
82	Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence. <i>Cancers</i> , 2021 , 13,	6.6	3
81	Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report. <i>Immunotherapy</i> , 2021 , 13, 1379-1386	3.8	0
80	An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study. <i>Japanese Journal of Clinical Oncology</i> , 2021 , 51, 484-491	2.8	1
79	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.. <i>World Journal of Clinical Oncology</i> , 2021 , 12, 1037-1046	2.5	
78	GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 17562872211054302	3.2	1
77	Neuroendocrine Differentiation of Prostate Cancer Is Not Systematically Associated with Increased 18F-FDG Uptake. <i>Diagnostics</i> , 2021 , 11,	3.8	3
76	The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 1198-1207	6.2	7
75	Immunotherapy retreatment: case report, review of the literature and proposal for the definition of different scenarios. <i>Immunotherapy</i> , 2021 , 13, 645-652	3.8	1
74	Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). <i>Frontiers in Oncology</i> , 2021 , 11, 682449	5.3	3
73	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. <i>Targeted Oncology</i> , 2021 , 16, 625-632	5	2
72	The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 1	8.8	5
71	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211019642	5.4	11

70	Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021 , 44, 121-125	2.7	5
69	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. <i>Journal of Clinical Pathology</i> , 2020 ,	3.9	1
68	The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study. <i>Cancers</i> , 2020 , 12,	6.6	11
67	Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020 , 140, 140-146	7.5	12
66	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 477-488	3.3	8
65	Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDia study. <i>Immunotherapy</i> , 2020 , 12, 151-159	3.8	8
64	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920968463	5.4	7
63	Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers. <i>Oncologist</i> , 2020 , 25, e1509-e1515	5.7	7
62	Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 291-298	3.3	18
61	Plasma AR status and cabazitaxel in heavily-treated metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019 , 116, 158-168	7.5	23
60	Primary mediastinal germ cell tumors. <i>Seminars in Oncology</i> , 2019 , 46, 107-111	5.5	29
59	Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 137, 154-164	7	2
58	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. <i>Clinical Cancer Research</i> , 2019 , 25, 3839-3846	12.9	90
57	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 529.e1-529.e7	2.8	4
56	Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1283-1289	3.8	12
55	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019 , 123, 98-105	5.6	48
54	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e903-e908	3.3	16
53	Plasma AR status and cabazitaxel in heavily-treated metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 203-203	2.2	0

52	Pazopanib as first line in METastatic RCC patients: A Real-world Italian experience (PAMERIT study) Preliminary results.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 611-611	2.2	
51	Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223. <i>Cancers</i> , 2019 , 12,	6.6	18
50	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2019 , 12,	6.6	14
49	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019 , 42, 42-45	2.7	12
48	Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience. <i>Anticancer Research</i> , 2018 , 38, 4913-4918	2.3	3
47	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e945-e951	3.3	22
46	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2018 , 29, 705-709	2.4	1
45	Safety and efficacy of abiraterone acetate (AA) in patients aged 75 or more with metastatic castration-resistant prostate cancer (mCRPC) in both pre-chemotherapy or post-chemotherapy settings: Real-life experience from thirteen Italian centers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 209-209	2.2	
44	Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature. <i>Immunotherapy</i> , 2018 , 10, 1123-1132	3.8	8
43	Enzalutamide in Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 1381-1392	5.2	7
42	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. <i>Immunotherapy</i> , 2018 , 10, 1229-1239	3.8	22
41	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 355-359.e1	3.3	22
40	First-Line Pazopanib in Non-clear-cell Renal carcinoma: The Italian Retrospective Multicenter PANORAMA Study. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e609-e614	3.3	30
39	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 541.e7-541.e13	2.8	9
38	Functional analysis of a CDKN2A 5'UTR germline variant associated with pancreatic cancer development. <i>PLoS ONE</i> , 2017 , 12, e0189123	3.7	1
37	International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer. <i>Health and Quality of Life Outcomes</i> , 2017 , 15, 97	3	15
36	FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4521-4521	2.2	9
35	Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4577-4577	2.2	2

34	Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma (mRCC): A G.I.O.N. trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16081-e16081	2.2	1
33	TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4601-TPS4601	2.2	
32	Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations. <i>Human Genetics</i> , 2016 , 135, 1241-1249	6.3	19
31	Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study. <i>Annals of Oncology</i> , 2016 , 27, vi252	10.3	2
30	Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e161-9	3.3	9
29	First-line pazopanib in non-clear cell renal carcinoma: The Italian retrospective multicenter PANORAMA study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16081-e16081	2.2	2
28	TARIBO trial: Targeted therapy with or without nephrectomy in metastatic renal cell carcinoma (mRCC) liquid biopsy for biomarkers discovery.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS4584-TPS4584	2.2	1
27	TRIBE-2 by GONO group: A phase III strategy study in the first- and second-line treatment of unresectable metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS3629-TPS3629	2.2	2
26	Hepatosplenic T-cell lymphoma with aberrant expression of serum β HCG: a case report. <i>Tumori</i> , 2015 , 101, e160-2	1.7	2
25	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015 , 68, 147-53	10.2	62
24	Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity. <i>World Journal of Gastroenterology</i> , 2015 , 21, 10688-96	5.6	9
23	Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography. <i>Cancer Imaging</i> , 2014 , 14, 10	5.6	9
22	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014 , 10, 975-83	3.6	38
21	Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. <i>Journal of Geriatric Oncology</i> , 2014 , 5, 156-63	3.6	21
20	Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 182-9	3.3	18
19	Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study. <i>Cancer</i> , 2013 , 119, 3429-35	6.4	23
18	Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 189-189	2.2	
17	Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy. <i>Familial Cancer</i> , 2012 , 11, 41-7	3	26

16	CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. <i>Journal of Medical Genetics</i> , 2012 , 49, 164-70	5.8	56
15	Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 253-253	2.2	3
14	Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. <i>Annals of Oncology</i> , 2011 , 22, 1236-1242	10.3	85
13	Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies. <i>Annals of Oncology</i> , 2011 , 22, 973-978	10.3	14
12	Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. <i>European Journal of Cancer</i> , 2009 , 45, 65-73	7.5	47
11	First-line single-agent cetuximab in patients with advanced colorectal cancer. <i>Annals of Oncology</i> , 2008 , 19, 711-6	10.3	34
10	Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1619-25	2.2	131
9	Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 388-98	9.7	105
8	Bevacizumab in the treatment of metastatic colorectal cancer. <i>Future Oncology</i> , 2007 , 3, 141-8	3.6	19
7	Predicting the risk of pancreatic cancer: on CDKN2A mutations in the melanoma-pancreatic cancer syndrome in Italy. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5336-7; author reply 5337-8	2.2	21
6	Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. <i>European Urology</i> , 2006 , 50, 1032-8; discussion 1038-9	10.2	51
5	Adjuvant Systemic Therapies in Patients with Colorectal Cancer: An Audit on Clinical Practice in Italy. <i>Tumori</i> , 2005 , 91, 472-476	1.7	5
4	The handling of metastatic colorectal cancer. <i>Annals of Oncology</i> , 2005 , 16 Suppl 2, ii141-3	10.3	1
3	Intra-Arterial Liver Chemotherapy and Hormone Therapy in Malignant Insulinoma: Case Report and Review of the Literature. <i>Tumori</i> , 2000 , 86, 475-479	1.7	14
2	BRCA1 and BRCA2 mutations in central and southern Italian patients. <i>Breast Cancer Research</i> , 2000 , 2, 307-10	8.3	25
1	BRCA1 and BRCA2 Gene Mutations in Breast/Ovarian Cancer Patients from Central and Southern Italy. <i>Disease Markers</i> , 1999 , 15, 96-96	3.2	78